Quarterly report pursuant to Section 13 or 15(d)

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)			1 Months Ended						3 Months Ended	6 Months Ended
EQUITY (Details Narrative) - USD ($)	Aug. 08, 2018	Mar. 03, 2017	May 31, 2018	Mar. 31, 2018	Mar. 27, 2018	Jun. 30, 2017	Apr. 19, 2017	Mar. 31, 2017	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Preferred stock, authorised									10,000,000	10,000,000		10,000,000
Preferred stock, par value (in dollars per share)									$ 0.0001	$ 0.0001		$ 0.0001
Common stock, authorised									490,000,000	490,000,000		490,000,000
Common stock, par value (in dollars per share)									$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, issued									0	0		0
Preferred stock, outstanding									0	0		0
Common stock, issued									73,560,622	73,560,622		70,278,622
Common stock, outstanding									73,040,622	73,040,622		70,278,622
Stock warrants issued										578,891
Warrants exercise price									$ 1.28	$ 1.28
Common shares issued for services										$ 467,000
Stock-based compensation expense										1,082,923	$ 266,467
Term							1 year
Refundable deposit										2,000,000
Aggregate intrinsic value of the warrants outstanding									$ 850,840	850,840
Aggregate intrinsic value of the warrants exercisable									850,840	850,840
Employee Stock Option [Member]
Aggregate fair value of options granted										337,523
Compensation and related benefits									79,193	151,480
Aggregate value of nonvested options									1,575,471	$ 1,575,471
Amortization of stock-based compensation expense										1 year 6 months 29 days
Intrinsic value of stock options outstanding									4,702,100	$ 4,702,100
Intrinsic value of stock options exercisable									2,272,599	2,272,599
Non Employee Stock Option [Member]
Compensation and related benefits									172,305	383,042
Aggregate value of nonvested options									303,319	$ 303,319
Amortization of stock-based compensation expense										3 months 29 days
Intrinsic value of stock options outstanding									630,000	$ 630,000
Intrinsic value of stock options exercisable									$ 315,000	$ 315,000
DOING Biomedical Technology Co., Ltd
Related party repayment obligation			$ 1,000,000	$ 200,000
Accredited investor \| Subsequent Event [Member]
Common stock issued, Shares	2,000,000
Common stock issued, Value	$ 2,000,000
Third party
Common stock repurchased, Shares					520,000
Common stock repurchased, Value					$ 522,500
Escrow agent
Share repurchase cost					$ 2,500
Subscription Agreement \| Private Placement [Member]
Stock warrants issued									218,391
Subscription Agreement \| Private Placement One [Member]
Stock warrants issued									151,235
Warrants exercise price									$ 1.62	$ 1.62
Subscription Agreement \| Private Placement Two [Member]
Stock warrants issued									5,960
Warrants exercise price									$ 1.85	1.85
Subscription Agreement \| Private Placement Three [Member]
Stock warrants issued									36,750
Warrants exercise price									$ 1.90	1.90
Subscription Agreement \| Private Placement Four [Member]
Stock warrants issued									24,446
Warrants exercise price									$ 2.24	$ 2.24
Subscription Agreement \| Four investor
Common shares sold for cash									$ 5,056,643
Common shares sold for cash (in shares)									3,107,000
Warrants term									5 years	5 years
Share price									$ 1.75	$ 1.75
Subscription Agreement \| Accredited investor
Common stock issued, Shares		3,000,000						2,000,000
Common stock issued, Value		$ 3,000,000
Subscription Agreement \| Accredited investor \| Avalon (Shanghai) Healthcare Technology Co., Ltd.
Annual interest						20.00%		20.00%
Principal amount										$ 2,000,000
Share price						$ 1.20		$ 1.20			$ 1.20
Term						3 years		3 years
Consulting agreements \| Three consulting companies
Common shares issued for services										$ 467,000
Common shares issued for services (in shares)										175,000
Stock-based compensation expense									$ 61,750	$ 61,750
Prepaid expense									$ 405,250	$ 405,250